Your browser doesn't support javascript.
loading
Reactivity to the p305 Epitope of the α1G T-Type Calcium Channel and Autoimmune-Associated Congenital Heart Block.
Markham, Androo J; Rasmussen, Sara E; Salmon, Jane E; Martinez-Ortiz, Wilnelly; Cardozo, Timothy J; Clancy, Robert M; Buyon, Jill P.
Afiliação
  • Markham AJ; Department of Medicine, New York University School of Medicine, New York, NY (A.J.M., S.E.R., R.M.C., J.P.B.).
  • Rasmussen SE; Department of Medicine, New York University School of Medicine, New York, NY (A.J.M., S.E.R., R.M.C., J.P.B.).
  • Salmon JE; Division of Rheumatology, Hospital for Special Surgery, New York, NY (J.E.S.).
  • Martinez-Ortiz W; Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY (W.M.O., T.J.C.).
  • Cardozo TJ; Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY (W.M.O., T.J.C.).
  • Clancy RM; Department of Medicine, New York University School of Medicine, New York, NY (A.J.M., S.E.R., R.M.C., J.P.B.).
  • Buyon JP; Department of Medicine, New York University School of Medicine, New York, NY (A.J.M., S.E.R., R.M.C., J.P.B.).
J Am Heart Assoc ; 4(5)2015 May 20.
Article em En | MEDLINE | ID: mdl-25994441
ABSTRACT

BACKGROUND:

Only 2% of mothers positive for anti-SSA/Ro (Ro) antibodies have children with congenital heart block (CHB). This study aimed to determine whether reactivity with p305, an epitope within the α1G T-type calcium channel, confers added risk over anti-Ro antibodies. METHODS AND

RESULTS:

Using sera from anti-Ro-exposed pregnancies resulting in offspring with CHB, no disease but CHB-sibling, and no disease and no CHB-sibling, as well as disease (lupus without anti-Ro) and healthy controls, reactivities were determined for binding to Ro60, p305, and an epitope within Ro60, p133-Ro60, which shares structural properties with p305, including key amino acids and an α-helical structure. Candidate peptides were further evaluated in an in vitro model that assessed the binding of maternal antibodies to apoptotic cells. In anti-Ro-positive mothers, anti-p305 autoantibodies (>3 SD above healthy controls) were detected in 3/59 (5%) CHB pregnancies, 4/30 (13%) unaffected pregnancies with a CHB-sibling, and 0/42 (0%) of unaffected pregnancies with no CHB-sibling. For umbilical bloods (61 CHB, 41 healthy with CHB sibling), no association of anti-p305 with outcome was detected; however, overall levels of anti-p305 were elevated compared to mothers during pregnancy in all groups studied. For anti-p133-Ro60, reactivity paralleled that of anti-p305. In the screen employing apoptotic cells, p133-Ro60, but not p305, significantly attenuated the binding of immunoglobulin G isolated from a mother whose child had CHB (42.1% reduced to 13.9%, absence/presence of p133-Ro60, respectively, P<0.05).

CONCLUSIONS:

These data suggest that anti-p305 is not a robust maternal marker for assessing increased risk of CHB during an anti-SSA/Ro pregnancy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Anticorpos Antinucleares / Canais de Cálcio Tipo T / Bloqueio Cardíaco Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Anticorpos Antinucleares / Canais de Cálcio Tipo T / Bloqueio Cardíaco Idioma: En Ano de publicação: 2015 Tipo de documento: Article